83 FR 53253 - Assisted Reproductive Technology (ART) Success Rates Reporting and Data Validation Procedures
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention Federal Register Volume 83, Issue 204 (October 22, 2018)
Centers for Disease Control and Prevention
Federal Register Volume 83, Issue 204 (October 22, 2018)
| Page Range | 53253-53256 | |
| FR Document | 2018-22991 |
[Federal Register Volume 83, Number 204 (Monday, October 22, 2018)] [Notices] [Pages 53253-53256] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2018-22991] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention [Docket No. CDC-2018-0054] Assisted Reproductive Technology (ART) Success Rates Reporting and Data Validation Procedures AGENCY: Department of Health and Human Services (HHS), Centers for Disease Control and Prevention (CDC). ACTION: Notice of availability. ----------------------------------------------------------------------- SUMMARY: On May 31, 2018, the Centers for Disease Control and Prevention (CDC) in the Department of Health and Human Services (HHS) requested comments on a plan to (1) revise the definition and characterization of Assisted Reproductive Technology (ART) success rates and (2) introduce clinic validation footnotes for the annual ART Fertility Clinic Success Rates Report. In the plan, CDC proposed to include the footnotes to identify clinics selected by CDC to participate in the validation process of the National ART Surveillance System (NASS) data and: (a) Do participate, (b) do participate and have major data discrepancies identified through this process, or (c) decline to participate in the data validation process. This notice responds to the comments received in response to the notice published on May 31, 2018 and announces the availability of the revised process for ART Success Rates Reporting and plans for revising Data Validation Procedures. FOR FURTHER INFORMATION CONTACT: Jeani Chang, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop F-74, Atlanta, Georgia 30341. Telephone: (770) 488-5200; email: ARTinfo@cdc.gov. Public Comment Summary and Responses CDC received three public comments to the docket. One comment was considered nonsubstantive because it was outside the scope of the docket. A second comment was supportive of CDC's planned approach for revising the definition of success rates and introducing clinic validation footnotes. The third comment contained concerns about CDC's planned clinic validation footnotes and the approach to clinic validation, and requested a clarification of the reporting requirements of embryo banking cycles. These suggestions, as well as CDC's responses, are included below: 1. ART success rates reporting: One commenter asked that CDC provide more details about reporting requirements of embryo banking cycles. Response: CDC thanks the commenter for this request. Egg/embryo banking cycles intended for pregnancy in the short term include cycles initiated with the intent of cryopreserving all eggs/embryos for subsequent transfers within 12 months. Egg/embryo banking cycles intended for pregnancy in the long term (often referred to as fertility preservation) include cycles where the patient did not start any transfer cycles within the 12 month period following the date on which the intended retrieval cycle started and one of the following: (1) The cycle intent was long term (>12 months) banking for fertility preservation prior to gonadotoxic medical treatments; or (2) The cycle intent was long term (>12 months) banking for other reasons and (a) at least one egg was retrieved, and (b) at least one egg or embryo was frozen. Specifics about the reporting process and requirements are described in ``Reporting of Pregnancy Success Rates [[Page 53254]] from Assisted Reproductive Technology (ART) Programs'' (80 FR 51811). 2. Clinic data validation and footnotes: A commenter expressed concern that discrepancies identified during on-site data validation would not be corrected prior to publication of the ART Fertility Clinic Success Rates Report. The commenter suggested that instead of including a footnote, identification of erroneous data (such as an incorrect number of reported cycles or pregnancy outcomes) should result in removing clinic success rates from ART Fertility Clinic Success Rates Report, and that erroneous data should not be included with data from other clinics. The commenter was also concerned that random selection of clinics under the current CDC validation system does not identify systematic reporting errors. The commenter suggested that targeted selection of clinics based on reporting characteristics that predict erroneously inflated ART success rates is a better approach to identify systematic reporting errors. Finally, the commenter was concerned that validation footnotes and the appendix may not be easily understood by the patients. Response: CDC thanks the commenter for expressing these concerns and for providing suggestions to improve reporting. CDC is considering these concerns and reviewing options for future years' data validation. CDC is withdrawing its pending proposal for data validation footnotes (83 FR 25009). If CDC determines that changes in data validation selection processes and/or footnotes are advisable, proposed changes will be published in the Federal Register for public comment. Appendix--Notice for Assisted Reproductive Technology (ART) Success Rates Reporting: A. Background Section 2(a) of Public Law 102-493 (42 U.S.C. 263a-1(a)), the Fertility Clinic Success Rate and Certification Act of 1992 (FCSRCA), requires that each assisted reproductive technology (ART) program report annually to the Secretary of the Department of Health and Human Services through the Centers for Disease Control and Prevention (CDC) pregnancy success rates achieved through assisted reproductive technology. The FCSRCA also requires CDC to annually publish and distribute to the public reported pregnancy success rates for each ART clinic. According to the FCSRCA, the definitions of pregnancy success rates should be developed in consultation with appropriate consumer and professional organizations, should take into account the effect on success rates of age, diagnosis, and other significant factors, and should include the live birth rate per attempted ovarian stimulation procedure and the live birth rate per successful oocyte retrieval. Specifics about the reporting process and requirements are described in ``Reporting of Pregnancy Success Rates from Assisted Reproductive Technology (ART) Programs'' (August 26, 2015; 80 FR (51811-51819)). Specifics about the definition and characterization of ART success rates were last described in ``Reporting of Pregnancy Success Rates from Assisted Reproductive Technology Programs'' (February 5, 2004; 69 FR (5548-5550)). Success rates for fresh, nondonor cycles were defined as: 1. The rate of pregnancy after completion of ART according to the number of all ovarian stimulation or monitoring procedures; 2. the rate of live birth after completion of ART according to the number of all ovarian stimulation or monitoring procedures, the number of oocyte retrieval processes, and the number of embryo (or zygote or oocyte) transfer procedures; 3. the rate of singleton live birth after completion of ART according to the number of all ovarian stimulation or monitoring procedures and the number of embryo (or zygote or oocyte) transfer procedures. Success rates for cycles using thawed embryos and cycles using donor oocytes or embryos were defined as: 4. the rate of live birth after completion of ART according to the number of embryo (or zygote or oocyte) transfer procedures; 5. the rate of singleton live birth after completion of ART according to the number of embryo (or zygote or oocyte) transfer procedures. Effective for reporting year 2017, CDC is implementing substantial changes to the definition and characterization of ART success rates due to changes in clinical practice and more variation in treatment options, including improvements in cryopreservation resulting in more segmentation of typical treatment cycles. The field of ART is moving toward the calculation and reporting of cumulative success rates where data collection systems can collect successes over all embryo transfers from a single oocyte retrieval or across several oocyte retrievals and embryo transfers. After consultation with consumer and professional organizations with expertise in ART, CDC will begin cumulative ART success rates reporting in reporting year 2017. The ART success rates described in this Federal Register notice shall replace those previously described in 2004. B. ART Procedures Among Patients Using Their Own Oocytes ART success rates for ART procedures among all patients using their own eggs are defined as: 1. The rate of live birth or singleton live birth resulting from the transfer of oocytes retrieved from the patient in the year prior to the reporting year or from the transfer of embryos created from oocytes retrieved from the patient in the year prior to the reporting year. For the purpose of this definition, transfer procedures must have started within 12 months of the start of the retrieval procedure. Oocytes must have been retrieved in the year prior to the reporting year in order to allow a full year to perform transfers of the retrieved oocytes (either in the prior reporting year or in the current reporting year). The live birth rate and singleton live birth rate will be presented according to the number of: a. All ovarian stimulation or monitoring procedures started from the year prior to the reporting year with the intent to retrieve oocytes from the patient. b. All ovarian stimulation or monitoring procedures started in the year prior to the reporting year with the intent to retrieve oocytes from the patient in which at least one oocyte was retrieved. c. All transfer procedures of at least one oocyte retrieved from the patient in the year prior to the reporting year, or of at least one embryo created from an oocyte retrieved from the patient in the year prior to the reporting year. For the purpose of this definition, egg or embryo transfer procedures must have started within 12 months of the start of the retrieval procedure. 2. The number of ovarian stimulation or monitoring procedures started in the year prior to the reporting year with the intent to retrieve oocytes from the patient presented according to the number of: a. Live births resulting from all transfers of at least one oocyte retrieved from the patient in the year prior to the reporting year, or transfers of at least one embryo created from an oocyte retrieved from the patient in the year prior to the reporting year. For the purpose of this definition, egg or embryo transfer procedures must have started within 12 months of the start of the retrieval procedure. Other rates for ART procedures among all patients using their own eggs are defined as follows (and may be provided publically at the ART program's discretion)-- 3. The rate of cancellation, implantation, pregnancy, live birth, [[Page 53255]] singleton live birth, multiple live birth, twin live birth, triplet or higher order live birth, preterm live birth, low birthweight live birth or term, normal birthweight and singleton live birth resulting from the transfer of oocytes retrieved from the patient in the year prior to the reporting year or the transfer of embryos created from oocytes retrieved from the patient in the year prior to the reporting year. For the purpose of this definition, transfer procedures must have started within 12 months of the start of the retrieval procedure. These other rates may be presented according to the number of: a. All ovarian stimulation or monitoring procedures started in the year prior to the reporting year with the intent to retrieve oocytes from the patient. b. All ovarian stimulation or monitoring procedures started in the year prior to the reporting year with the intent to retrieve oocytes from the patient in which at least one oocyte was retrieved. c. All transfer procedures of at least one oocyte retrieved from the patient in the year prior to the reporting year, or of at least one embryo created from an oocyte retrieved from the patient in the year prior to the reporting year. For the purpose of this definition, egg or embryo transfer procedures must have started within 12 months of the start of the retrieval procedure. d. All first, second, third, or more transfer procedures after retrieval of at least one oocyte from the patient in the year prior to the reporting year, or of at least one embryo created from an oocyte retrieved from the patient in the year prior to the reporting year. For the purpose of this definition, egg or embryo transfer procedures must have started within 12 months of the start of the retrieval procedure. Rates for ART procedures among new ART patients (i.e. patients that have never had a prior ART cycle ever) using their own oocytes are defined as-- 4. The rate of live birth resulting from the transfer of oocytes or embryos from all first intended oocyte retrievals presented according to the number of: a. ART patients who reported at the start of the retrieval procedure that they had no prior ART stimulations and no prior frozen ART procedures. For the purpose of this definition, the retrieval procedure must have started in the year prior to the reporting year. 5. The rate of live birth resulting from the transfer of oocytes or embryos from all first or second intended oocyte retrievals presented according to the number of: a. ART patients who reported at the start of the retrieval procedure that they had no prior ART stimulations and no prior frozen ART procedures. For the purpose of this definition, the retrieval procedure must have started in the year prior to the reporting year. 6. The rate of live birth resulting from the transfer of oocytes or embryos from all intended oocyte retrievals presented according to the number of: a. ART patients who reported at the start of the retrieval procedure that they had no prior ART stimulations and no prior frozen ART procedures. For the purpose of this definition, the retrieval procedure must have started in the year prior to the reporting year. 7. The number of ovarian stimulation or monitoring procedures started in the year prior to the reporting year with the intent to retrieve oocytes from the patient presented according to the number of: a. ART patients who reported at the start of the retrieval procedure that they had no prior ART stimulations and no prior frozen ART procedures. 8. The number of transfer procedures of at least one oocyte retrieved from the patient in the year prior to the reporting year, or of at least one embryo created from an oocyte retrieved from the patient in the year prior to the reporting year presented according to the number of: a. Ovarian stimulation or monitoring procedures started in the year prior to the reporting year with the intent to retrieve oocytes from the patient. For the purpose of this definition, egg or embryo transfer procedures must have started within 12 months of the start of the retrieval procedure. Also, ART patients must have reported at the start of the retrieval procedure that they had no prior ART stimulations and no prior frozen ART procedures. C. ART Procedures Among Patients Using Oocytes or Embryos From a Donor Success rates for ART procedures among patients using oocytes or embryos from a donor are defined as-- 9. The rate of live birth or singleton live birth presented according to the number of: a. Transfer procedures of at least one donor egg, embryo created from a donor egg, or donated embryo started in the current reporting year. Other rates for ART procedures among patients using oocytes or embryos from a donor are defined as follows (and may be provided publically at the ART program's discretion): 10. The rate of cancellation, implantation, pregnancy, live birth, singleton live birth, multiple live birth, twin live birth, triplet or higher order live birth, preterm live birth, low birthweight live birth, or term, normal birthweight and singleton live birth presented according to the number of: a. ART procedures to prepare a patient (recipient) for the transfer of at least one donor egg, embryo created from a donor egg, or donated embryo, started in the current reporting year. b. Transfer procedures of at least one donor egg, embryo created from a donor egg, or donated embryo started in the current reporting year. D. ART Procedures Among All Patients and All Cycle Types At the discretion of the ART program, ART reporting also may include: 11. The number, average number or percentage of ART procedures or ART patients with certain characteristics, such as: a. Patient characteristics (e.g. patient age or reason for ART). b. ART procedure characteristics (e.g. type of treatment (fertility preservation, short term banking, in vitro fertilization, gamete intrafallopian transfer, zygote intrafallopian transfer), stimulation protocol, source of the oocytes or embryos (patient or donor), the state of the oocytes or embryos (fresh or frozen), the intent of the procedure, the use of prenatal genetic diagnosis or screening, the use of intracytoplasmic sperm injection, the use of assisted hatching, the use of a gestational carrier, the stage of the embryo at transfer, or the number of embryos transferred). All ART patient and procedure characteristics, ART success rates, and other rates for patients using their own oocytes as well as for patients using oocytes or embryos from a donor may be stratified by CDC by factors thought to influence the outcome of an ART procedure. 12. Factors for stratification may include: a. Characteristics of the ART patient such as patient age or reason for ART. b. Characteristics of the ART procedure such as type of treatment (fertility preservation, short term banking, in vitro fertilization, gamete intrafallopian transfer, zygote intrafallopian transfer), stimulation protocol, the source of the oocytes or embryos (patient or donor), the state of the oocytes or embryos (fresh or frozen), the intent of the procedure, the use of prenatal genetic diagnosis or screening, the use of intracytoplasmic sperm injection, the use of assisted hatching, the use of a gestational carrier, the stage of the embryo at transfer, or the number of embryos transferred. [[Page 53256]] Dated: October 17, 2018. Sandra Cashman, Executive Secretary, Centers for Disease Control and Prevention. [FR Doc. 2018-22991 Filed 10-19-18; 8:45 am] BILLING CODE 4163-18-P
![Federal Register / Vol. 83, No. 204 / Monday, October 22, 2018 / Notices 53253
This is a revised Information The updated Scorecard is based on a of the strategies and interventions
Collection Request (ICR) supporting a 2017 pilot test to determine the validity contained in the questions has been
broader group of employers to access and reliability involving 89 employers completed. This will streamline future
the updated and pilot tested Scorecard, (each represented by two knowledgeable information collection and minimize
a web-based worksite organizational employees) who completed the survey additional response time.
assessment, to regularly assess their and follow-up telephone interviews to
CDC will continue to provide
workplace health programs and gather general impressions of the
practices. Scorecard users will create a Scorecard—particularly the new outreach to, and register approximately
user account, complete the online modules—and also to discuss items 800 employers per year to use the online
assessment and receive an immediate where there were discrepancies (and Scorecard survey in their workplace
feedback report that summarizes the items that were left blank) to understand health program assessment, planning,
current status of their worksite health the respondent’s interpretation and and implementation efforts, which is
program; identifies gaps in current perspective of their answers to these open to employers of all sizes, industry
programming; benchmarks individual questions. The revised instrument sectors, and geographic locations across
employer results against other users of includes some reorganization of the the country. OMB approval is requested
the system; and provides access to instrument and minor revisions, for three years. Participation is
worksite health tools and resources to particularly to the new modules/ voluntary and there are no costs to
address employer gaps and priority questions, to better explain and define respondents other than their time.
program areas. the context, concepts, or administration
ESTIMATED ANNUALIZED BURDEN HOURS
Average
Number of
Number of burden per Total burden
Type of respondent Form name responses per
respondents response (in hrs)
respondent (in hrs)
Employers ......................................... CDC Worksite Health ScoreCard 800 1 5/60 67
Registration.
CDC Worksite Health Scorecard ..... 800 1 45/60 600
Total ........................................... ........................................................... ........................ ........................ ........................ 667
Jeffrey M. Zirger, to include the footnotes to identify about CDC’s planned clinic validation
Acting Chief, Information Collection Review clinics selected by CDC to participate in footnotes and the approach to clinic
Office, Office of Scientific Integrity, Office the validation process of the National validation, and requested a clarification
of the Associate Director for Science, Office ART Surveillance System (NASS) data of the reporting requirements of embryo
of the Director, Centers for Disease Control and: (a) Do participate, (b) do participate banking cycles. These suggestions, as
and Prevention.
and have major data discrepancies well as CDC’s responses, are included
[FR Doc. 2018–22940 Filed 10–19–18; 8:45 am] identified through this process, or (c) below:
BILLING CODE 4163–18–P decline to participate in the data 1. ART success rates reporting: One
validation process. This notice responds commenter asked that CDC provide
to the comments received in response to more details about reporting
DEPARTMENT OF HEALTH AND the notice published on May 31, 2018 requirements of embryo banking cycles.
HUMAN SERVICES and announces the availability of the Response: CDC thanks the commenter
revised process for ART Success Rates for this request. Egg/embryo banking
Centers for Disease Control and cycles intended for pregnancy in the
Prevention Reporting and plans for revising Data
Validation Procedures. short term include cycles initiated with
[Docket No. CDC–2018–0054] FOR FURTHER INFORMATION CONTACT: the intent of cryopreserving all eggs/
Jeani Chang, Division of Reproductive embryos for subsequent transfers within
Assisted Reproductive Technology 12 months. Egg/embryo banking cycles
Health, National Center for Chronic
(ART) Success Rates Reporting and intended for pregnancy in the long term
Disease Prevention and Health
Data Validation Procedures (often referred to as fertility
Promotion, Centers for Disease Control
AGENCY: Department of Health and and Prevention, 4770 Buford Highway preservation) include cycles where the
Human Services (HHS), Centers for NE, Mailstop F–74, Atlanta, Georgia patient did not start any transfer cycles
Disease Control and Prevention (CDC). 30341. Telephone: (770) 488–5200; within the 12 month period following
email: ARTinfo@cdc.gov. the date on which the intended retrieval
ACTION: Notice of availability.
cycle started and one of the following:
SUMMARY: On May 31, 2018, the Centers Public Comment Summary and (1) The cycle intent was long term (>12
for Disease Control and Prevention Responses months) banking for fertility
(CDC) in the Department of Health and CDC received three public comments preservation prior to gonadotoxic
Human Services (HHS) requested to the docket. One comment was medical treatments; or (2) The cycle
daltland on DSKBBV9HB2PROD with NOTICES
comments on a plan to (1) revise the considered nonsubstantive because it intent was long term (>12 months)
definition and characterization of was outside the scope of the docket. A banking for other reasons and (a) at least
Assisted Reproductive Technology second comment was supportive of one egg was retrieved, and (b) at least
(ART) success rates and (2) introduce CDC’s planned approach for revising the one egg or embryo was frozen. Specifics
clinic validation footnotes for the definition of success rates and about the reporting process and
annual ART Fertility Clinic Success introducing clinic validation footnotes. requirements are described in
Rates Report. In the plan, CDC proposed The third comment contained concerns ‘‘Reporting of Pregnancy Success Rates
VerDate Sep<11>2014 18:12 Oct 19, 2018 Jkt 247001 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 E:\FR\FM\22OCN1.SGM 22OCN1](https://thefederalregister.org/doc/83_FR_53457/page/1.svg)
![53256 Federal Register / Vol. 83, No. 204 / Monday, October 22, 2018 / Notices
Dated: October 17, 2018. health program; stability evaluation of proposed collection of information,
Sandra Cashman, active gas wells in longwall abutment including the validity of the
Executive Secretary, Centers for Disease pillars; and durable support for western methodology and assumptions used;
Control and Prevention. US underground metal mines. The (c) Enhance the quality, utility, and
[FR Doc. 2018–22991 Filed 10–19–18; 8:45 am] meeting will also include updates from clarity of the information to be
BILLING CODE 4163–18–P the NIOSH Associate Director for collected;
Mining, the Spokane Mining Research (d) Minimize the burden of the
Division, and the Pittsburgh Mining collection of information on those who
DEPARTMENT OF HEALTH AND Research Division. Agenda items are are to respond, including, through the
HUMAN SERVICES subject to change as priorities dictate. use of appropriate automated,
The Chief Operating Officer, Centers electronic, mechanical, or other
Centers for Disease Control and for Disease Control and Prevention, has technological collection techniques or
Prevention been delegated the authority to sign other forms of information technology,
Federal Register notices pertaining to e.g., permitting electronic submission of
Mine Safety and Health Research announcements of meetings and other responses; and
Advisory Committee (MSHRAC) committee management activities, for (e) Assess information collection
AGENCY: Centers for Disease Control and both the Centers for Disease Control and costs.
Prevention (CDC), Department of Health Prevention and the Agency for Toxic
To request additional information on
and Human Services (HHS). Substances and Disease Registry.
the proposed project or to obtain a copy
ACTION: Notice of meeting. Sherri Berger, of the information collection plan and
Chief Operating Officer, Centers for Disease instruments, call (404) 639–7570 or
SUMMARY: In accordance with the Control and Prevention. send an email to omb@cdc.gov. Direct
Federal Advisory Committee Act, the [FR Doc. 2018–22988 Filed 10–19–18; 8:45 am] written comments and/or suggestions
CDC announces the following meeting regarding the items contained in this
BILLING CODE 4163–19–P
for the Mine Safety and Health Research notice to the Attention: CDC Desk
Advisory Committee (MSHRAC). This Officer, Office of Management and
meeting is open to the public, limited DEPARTMENT OF HEALTH AND Budget, 725 17th Street NW,
only by the space available. The meeting HUMAN SERVICES Washington, DC 20503 or by fax to (202)
room accommodates approximately 38 395–5806. Provide written comments
people. If you wish to attend in person Centers for Disease Control and within 30 days of notice publication.
or by phone, please contact Marie Prevention
Chovanec by email at MChovanec@ Proposed Project
[30Day–19–18UF]
cdc.gov or by phone at 412–386–5302 at Evidence to Inform Standards that
least 5 business days in advance of the Agency Forms Undergoing Paperwork Ensure Turnout Gear Remains
meeting. Reduction Act Review Protective Throughout Its Lifecycle—
DATES: The meeting will be held on New—National Institute for
November 29, 2018, 8 a.m.–4 p.m., MST In accordance with the Paperwork
Occupational Safety and Health
and on November 30, 2018, 8 a.m.–12 Reduction Act of 1995, the Centers for
(NIOSH), Centers for Disease Control
p.m. MST. Disease Control and Prevention (CDC)
and Prevention (CDC).
has submitted the information
ADDRESSES: University of Arizona,
collection request titled Assessment of Background and Brief Description
ENR2 Building, Room S215, 1064 E.
Evidence to Inform Standards that
Lowell Street, Tucson, AZ 85721 United Turnout gear is a type of personal
Ensure Turnout Gear Remains
States. protective equipment used by the 1.1
Protective Throughout Its Lifecycle to
FOR FURTHER INFORMATION CONTACT: million U.S. fire fighters to shield the
the Office of Management and Budget
Jeffrey H. Welsh, Designated Federal (OMB) for review and approval. CDC body from carcinogens, flames, heat,
Officer, MSHRAC, NIOSH, CDC, 626 previously published a ‘‘Proposed Data and chemical/biological agents. It serves
Cochrans Mill Road, Pittsburgh, PA Collection Submitted for Public as a barrier to external hazards while
15236, telephone 412–386–4040; email Comment and Recommendations’’ simultaneously allowing for the escape
juw5@cdc.gov. notice on April 12, 2018 to obtain of metabolic heat to prevent elevated
SUPPLEMENTARY INFORMATION: comments from the public and affected core body temperatures. To provide the
Purpose: This committee is charged agencies. CDC received one comment necessary performance characteristics,
with providing advice to the Secretary, related to the previous notice. This turnout gear design is complex,
Department of Health and Human notice serves to allow an additional 30 consisting of three major layers that
Services; the Director, CDC; and the days for public and affected agency work as a composite—a thermal liner, a
Director, NIOSH, on priorities in mine comments. moisture barrier, and an outer shell.
safety and health research, including CDC will accept all comments for this Consensus standards provide
grants and contracts for such research, proposed information collection project. performance requirements and
30 U.S.C. 812(b)(2), Section 102(b)(2). The Office of Management and Budget retirement criteria for turnout gear. The
Matters to be Considered: The agenda is particularly interested in comments retirement criteria is based on visual
will include discussions on mining that: inspections and a 10-year age cap with
safety and health research projects and (a) Evaluate whether the proposed visual inspection being less effective for
daltland on DSKBBV9HB2PROD with NOTICES
outcomes, including real-time DPM collection of information is necessary the moisture barrier and thermal liner
monitor; industrial minerals sector for the proper performance of the layers. Recent data of turnout gear
research priorities; MSHRAC metal functions of the agency, including donated from fire departments
mine automation workgroup report; whether the information will have demonstrates that turnout gear from 2 to
cemented backfill research; recent practical utility; 10 years old was unable to meet all
research in coal mine explosion and fire (b) Evaluate the accuracy of the performance requirements. Thus, under
prevention; engaging in the miner agencies estimate of the burden of the the current retirement criteria, turnout
VerDate Sep<11>2014 18:12 Oct 19, 2018 Jkt 247001 PO 00000 Frm 00051 Fmt 4703 Sfmt 4703 E:\FR\FM\22OCN1.SGM 22OCN1](https://thefederalregister.org/doc/83_FR_53457/page/4.svg)
Document Created: 2018-10-20 01:49:32
Document Modified: 2018-10-20 01:49:32
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice of availability. | |
| Contact | Jeani Chang, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop F-74, Atlanta, Georgia 30341. Telephone: (770) 488-5200; email: [email protected] | |
| FR Citation | 83 FR 53253 |
2024 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR